PubMed Central
Read the original →
One-year relapse rates have ranged from 28 to 44%, and enduring psychosocial impairment despite symptomatic recovery has been described in a substantial number of patients.
Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy - PMC
PubMed Central High trust
Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis - PMC
Improving Treatment Adherence in Bipolar Disorder: A Review of Current Psychosocial Treatment Efficacy and Recommendations for Future Treatment Development - PMC
Sleep loss as a trigger of mood episodes in bipolar disorder: individual differences based on diagnostic subtype and gender - PMC
Cognitive impairment in manic bipolar patients: important, understated, significant aspects - PMC